New Code
2017: 58674- Laparoscopic ablation of
Uterine Fibroid Tumors
February 4, 2017
CPT has granted coders a new code for the laparoscopic
ablation of uterine fibroid tumors. As
of January 1, 2017 the code is officially denoted as 58674 Laparoscopy, surgical, ablation of uterine fibroid(s), including
intraoperative ultrasound guidance and monitoring, radiofrequency. The addition of this new code by CPT
marks another successful transition of a code from the Category III code 0336T Laparoscopy, surgical, ablation of uterine
fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency. Category III codes are the temporary codes
set forth by CPT for emerging technology, services and procedures. The usage of this code as a Category III
code, allowed for the collection of specific data and its usage of code O336T code
for ablation of fibroid tumors has allowed for CPT to create a permanent CPT
code for this new technology.
The usage and transition of a Category III code to a permanent CPT code
is a very good thing. This allows for a
solid RVU value allocation to the code, and insurance payers will also put this
into their payment code base for standardized payment. However, some insurance payers may still
consider this to be an “experimental” code, so it is advisable to call the
carrier prior to the procedure being performed to inquire about payment of this
procedure with the new CPT code.
The new CPT code 58674 is primarily targeted for usage with the procedure
known as Laparoscopic Radiofrequency Volumetric Thermal Ablation (RFVTA). RFVTA is used to destroy uterine fibroids,
yet preserve the uterus. This is
revolutionary for some women who still may want to pursue pregnancy, or simply
to avoid major surgery such as hysterectomy, to definitively remove fibroid
tumors from the uterus.
Clinical indications
and documentation
Uterine fibroids are benign, muscular tumors in a woman's uterus that can
cause heavy bleeding, painful periods, pressure, and abdominal pressure, pain
and distention. According to the
National Institute of Health (NIH) at least 70% of women in the US will develop
fibroid tumors. Fibroids are a significant women’s health issue, and symptoms
can be very mild, to very extreme. The American
Congress of Obstetricians and Gynecologists (ACOG) has stated that 39% of all
hysterectomies are due to fibroid tumors and the issues related to those tumors. Hysterectomy has been one of the more
“traditional” methods for relief of fibroid uterine tumors. The usage of a less invasive procedure that
is performed laparoscopically is becoming more popular with surgeons and
patients alike.
In women who have symptoms, the most common symptoms of uterine fibroids
include:
·
Heavy menstrual bleeding.
·
Menstrual periods lasting more than a week.
·
Pelvic pressure or pain.
·
Frequent urination.
·
Difficulty emptying the bladder.
·
Constipation.
·
Backache or leg pains
The ablation of these fibroid tumors via a laparoscopically delivered
system of direct ablation to the uterine fibroid allows the patient to
alleviate the tumor, and preserve the uterus, thereby avoiding the effects of a
hysterectomy or major surgery for elimination of these tumors.
Clinically, this procedure is considered “minimally invasive” and is
performed as an outpatient procedure, and the patient can return to a normal
lifestyle within 2-3 days post procedure.
The procedure allows the surgeon to ablate targeted fibroids within the
uterine cavity. The surgeon the utilizes
the laparoscopic tools to specifically targe and deliver thermal radiofrequency
energy to the specific fibroid tumor with precise tip inserted into the fibroid itself. With this needle/tip the surgeon can then
control the amount of thermal energy need to destroy the fibroid tumor. Ultrasound
guidance allows the surgeon to visualize each tumor and the precise location of
where the needle/tip of the tools are to be placed for successful ablation of
the tumors.
RVU’s and Payment
Considerations
With any new CPT code, pricing and payment is something to be considered
if the physician has decided to include this into their practice. Below is the table from CMS that outlines the
National RVU’s allocated to code 58674.
This information can be accessed through the CMS link
As you can see from the above table this represents the National Payment
indicators from CMS, and therefore may not represent what is the actual RVU
values for your particular CMS locality.
CMS does allow for payment of this procedure, however many private
insurers may still consider this an “experimental” procedure and now allow for
payment of this procedure under their specific policies and contracts.
If the patient and physician have decided to pursue this method of
surgical intervention, it is advisable to do a thorough pre-authorization with
the patients’ insurance carrier to determine if they will pay for this new
technology. If the patient’s carries
does not pay for this procedure, then you should collect up-front and/or make
payment arrangements with the patient.
However, this does not preclude you, as the coder/biller from requesting
a pre-authorization request for consideration of payment for this code based
upon the patients’ medical necessity and the adoption of this procedure by CPT
as a permanent code into the codeset, and CMS’s adoption of RVU’s. In addition, a coder/biller can still file a
claim with the patients’ insurance post procedure and submitting the operative
notes and a formal request for payment.
Case Example
History: L.W. is a 44-year-old woman (G2P2) with a
2-year history of menorrhagia and severe dysmenorrhea but no intermenstrual
spotting or bleeding. We reviewed the failure of controlling her symptoms using
hormonal methods, without success.
Examination: Palpation reveals
that patient has an irregular, nontender uterus 8 weeks in size. Ultrasound
reports for the Transvaginal
ultrasonography shows two deep, prominent, intramural fibroids. The first is 2
cm by 3 cm in size in the left lateral uterus, adjacent to the endometrial
stripe. The second fibroid is 3 cm by 4 cm in the fundal region.
Sonohysterography reveals no intracavitary fibroids, although the left lateral
myoma has distorted the endometrial cavity.
Medical Decision
Making: The patient is seeking removal of her fibroids but would like to
preserve her uterus, if at all possible.
We have decided to pursue uterine-sparing fibroid treatment, performed
laparoscopically instead of a hysterectomy.
Patient has signed all appropriate consents and we will contact her
insurance carrier for pre-authorization and confirmation.
Operative
Session/report:
Utilizing the RFVTA technique we begin with a standard 5-mm laparoscopic
infraumbilical port for the camera and video laparoscope. Placee a 12-mm port in the midline,
suprapubically at the level of the uterus, and inserted the laparoscopic
ultrasound probe. With the laparoscope in place I began the mapping of the
uterus and outlined plan with the surgical team with the approach to destroy
the fibroids.
I then inserted the handpiece containing the radiofrequency needle
through the abdominal wall under laparoscopic visualization and placed the
needle into the targeted fibroid using both laparoscopic and ultrasound
guidance. I then accessed the first fibroid, in the left lateral uterus and
deployed the needle array to the maximum diameter necessary to begin the destruction.
I then engaged the radiofrequency generator and set it for optimal destruction
of the 2 x 3 cm fibroid, The fibroid was then ablated and destroyed without
damage to the surrounding healthy myometrium. I then performed this same
procedure upon the second fibroid in the fundal region. This fibroid measured 3 x 4 cm with optimal
destruction. Treatment is complete, and
confirmed I retracted the needle array.
I then coagulated the needle track during withdrawal of the probe, and
confirmed hemostasis of all surgical areas within the uterine cavity. All sponge and instruments counts were
correct and accounted for. The patient
was then taken to recovery area in good condition. Patient to be discharged the same day. I will see the patient back in-office on day 3
for a postoperative check.
Wrapping it up
As a coder, remember to code what you know, and do not assume. If in doubt, or the documentation does not
appear to be clear or is confusing, query the provider. Good patient care requires the provider to
accurately reflect the patient care via their documentation in the medical
record. Our job, as a coder, is to correlate
the coding and billing to reflect the medical that was documented and provided
by the physician. If you are unsure
about the coding guidelines utilize your resources such as CPT, ICD-10cm,
ICD-10pcs and HCPCS.
Lori-Lynne A. Webb, CPC,
CCS-P, CCP, CDIP, CHDA, COBGC and ICD10 cm/pcs Ambassador/trainer is an
E&M, and Procedure based Coding, Compliance, Data Charge entry and HIPAA
Privacy specialist, with over 20 years of experience. Lori-Lynne’s coding
specialty is OB/GYN office & Hospitalist Services, Maternal Fetal Medicine,
OB/GYN Oncology, Urology, and general surgical coding. She can be reached via
e-mail at webbservices.lori@gmail.com or you can also find current coding
information on her blog site: http://lori-lynnescodingcoachblog.blogspot.com/.